Surface, but Not Age, Impacts Lower Limb Joint Work during Walking and Stair Ascent

Older adults often suffer an accidental fall when navigating challenging surfaces during common locomotor tasks, such as walking and ascending stairs. This study examined the effect of slick and uneven surfaces on lower limb joint work in older and younger adults while walking and ascending stairs. Fifteen young (18–25 years) and 12 older (\u3e65 years) adults had stance phase positive limb and joint work quantified during walking and stair ascent tasks on a normal, slick, and uneven surface, which was then submitted to a two-way mixed model ANOVA for analysis. The stair ascent required greater limb, and hip, knee, and ankle work than walking (all p \u3c 0.001), with participants producing greater hip and knee work during both the walk and stair ascent (both p \u3c 0.001). Surface, but not age, impacted positive limb work. Participants increased limb (p \u3c 0.001), hip (p = 0.010), and knee (p \u3c 0.001) positive work when walking over the challenging surfaces, and increased hip (p = 0.015), knee (p \u3c 0.001), and ankle (p = 0.010) work when ascending stairs with challenging surfaces. Traversing a challenging surface during both walking and stair ascent tasks required greater work production from the large proximal hip and knee musculature, which may increase the likelihood of an accidental fall in older adults

Surface, but Not Age Impact Lower Limb Joint Work During Walk and Stair Ascent

During common locomotor activates, such as walk or stair negotiation, older adults exhibit unfavorable lower limb biomechanical changes, including diminished joint torque and power, and proximal mechanical work redistribution that may increase their fall risk. Twelve young (18 to 25 years) and 12 older (\u3e 65 years) adults performed a walk and stair ascent task on a normal, slick, and uneven surface. For each walk and stair ascent trial, synchronous 3D marker trajectories and GRF data were collected. Stance phase positive limb and joint work, and relative joint work were submitted to statistical analysis. Ascending stairs required more positive work than the walk, particularly from the knee, which may increase fall risk. Yet, both walking and ascending stairs over a challenging surface required more, proximally distributed work

Surface, but Not Age Impacts Lower Limb Joint Work During Stair Ascent

Introduction: Age-related loss in lower limb strength, particularly at the ankle, may impair older adults (over 65 years of age) mobility, and result in biomechanical deficits compared to their younger counterparts. Older adults tend to walk slower with shorter steps and exhibit diminished ankle joint kinetics (i.e., moment, power and work). Although the compromised ankle function leads older adults to produce smaller ankle joint torques and power output, reducing forces to propel the center of mass forward, it is unclear if they redistributed, or increase hip or knee work to safely walk, particularly when challenged with an uneven or slick surface. Objective: To compare positive lower limb work for young and older adults when walking over challenging surfaces, and determine whether redistributed power output. Methods: Twenty-eight (16 young, 18 to 25 years and 12 older, over 65 years) adults had positive work in the lower limb quantified when walking a self-selected speed over three surfaces (normal, uneven, and slick). Total limb, hip, knee and ankle positive work, and relative effort (% of total) at each joint were submitted to RM ANOVA to test main effect and interaction between surface (normal, uneven, and slick) and age (young and older adults). Results: Surface, but not age impact positive lower limb work. Surface impacted total limb (p=0.000), hip (p=0.007) and knee (p=0.001) positive work. The limb and knee produced more positive work on the uneven compared normal (

Multiple Health Behavior Changes in a Cancer Prevention Intervention for Construction Workers, 2001-2003

Introduction: Few multiple behavior change interventions have addressed tobacco use in conjunction with fruit and vegetable consumption, particularly among high-risk blue-collar workers. Tools for Health, a cancer prevention intervention for construction laborers, was effective in achieving behavior change for smoking cessation and fruit and vegetable consumption separately. This study examines whether addressing smoking and fruit and vegetable consumption was successful in achieving positive change for both behaviors. We also explored possible explanations for the relationship between behavior changes in these 2 behavioral domains. Methods: We retrospectively analyzed data from a randomized controlled trial testing a smoking cessation and fruit and vegetable consumption intervention for construction workers. We used survey data from 300 intervention participants to answer our primary research question: Did participants who reported being smokers at baseline successfully quit smoking and increase their fruit and vegetable consumption by the end of the intervention? We used qualitative data from 16 small group discussions to help interpret these results. Results: Tools for Health participants achieved substantial levels of smoking cessation and increased their fruit and vegetable consumption, concurrently, during the course of the intervention. Conclusion: This study provides evidence that pairing smoking cessation with increasing fruit and vegetable consumption can be successful in a multiple behavior change intervention designed for high-risk blue-collar workers. Further, our findings provide potential directions for examining why this pairing might be complementary

Probing Star Formation at Low Metallicity: The Radio Emission of Super Star Clusters in SBS0335-052

We present high-resolution radio continuum observations of the nascent starburst in the metal-poor galaxy SBS 0335-052. These radio data were taken with the Very Large Array and include observations at 0.7cm, 1.3cm, 2cm, 3.6cm, and 6cm. These observations enable us to probe the thermal radio nebulae associated with the extremely young star-forming regions in this galaxy. Two discrete and luminous star-forming regions are detected in the south of the galaxy that appear to be associated with massive star clusters previously identified at optical wavelengths. However, the remaining optically-identified massive star clusters are not clearly associated with radio emission (either thermal or non-thermal) down to the sensitivity limits of these radio data. The spectral energy distributions of the two radio-detected clusters are consistent with being purely thermal, and the entire region has an inferred ionizing flux of ~1.2 x 10^ 53 s^-1, which is equivalent to ~12,000 "typical" O-type stars (type O7.5 V). The observations presented here have resolved out a significant contribution from diffuse non-thermal emission detected previously, implying a previous episode of significant star formation. The current star formation rate (SFR) for this southern region alone is ~1.3 M_sun yr^-1, or ~ 23M_sun yr^-1 kpc^-2. This SFR derived from thermal radio emission also suggests that previous optical recombination line studies are not detecting a significant fraction of the current star formation in SBS 0335-052. From model fits to the radio spectral energy distribution, we infer a global mean density in the two youngest clusters of n_e > 10^3-10^4 cm^-3. In addition, a comparison between the compact and diffuse radio emission indicates that up to ~50% of the ionizing flux could be leaking out of the compact HII regions.Comment: accepted AJ, 14 pages, 5 figure

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

BACKGROUND: The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients. METHODS: A double-blind, randomized, multicenter study was conducted in 617 patients with OA of the knee. The base study was 14 weeks in duration and consisted of 2 parts; in Part I (6 weeks), patients were allocated to once daily oral etoricoxib 5, 10, 30, 60, 90 mg or placebo. In Part II (8 weeks); the placebo, etoricoxib 5 and 10 mg groups were reallocated to etoricoxib 30, 60, or 90 mg qd or diclofenac 50 mg t.i.d. Treatment was continued for consecutive 12 and 26 week extensions. Primary efficacy endpoints were the WOMAC VA 3.0 pain subscale and investigator global assessment of disease status. Safety and tolerability were assessed by collecting adverse events throughout the study. RESULTS: Compared with placebo, the etoricoxib groups displayed significant (p < 0.05), dose-dependent efficacy for all primary endpoints in Part I; efficacy was maintained throughout the 52 weeks of the study. During the 46-week active-comparator controlled period, the etoricoxib groups demonstrated clinical efficacy that was similar to that of diclofenac 150 mg and was generally well tolerated, with a lower incidence of gastrointestinal (GI) nuisance symptoms compared with diclofenac (13.1, 14.7, and 13.5% for etoricoxib 30, 60, and 90 mg, respectively compared with 22.5% for diclofenac). CONCLUSION: In this extension study, etoricoxib, at doses ranging from 30 to 90 mg, demonstrated a maintenance of significant clinical efficacy in patients with OA through 52 weeks of treatment. Etoricoxib displayed clinical efficacy similar to diclofenac 150 mg and was generally well tolerated

Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), and insulin-like growth factor binding protein-3 (IGFBP-3) were measured in frozen serum samples from 1051 men with cancer and 3142 controls in a nested case–control study from the British United Provident Association (BUPA) study cohort and associations with 14 cancers were examined, including prostate, colorectal, and lung. A meta-analysis of studies on these three cancer sites was also conducted. In the meta-analysis the odds ratio between the highest quartile IGF-1 group and the lowest quartile group was 1.31 (95% confidence interval (CI): 1.03–1.67) for prostate, 1.37 (1.05–1.78) for colorectal and 1.02 (0.80–1.31) for lung cancer, and for IGF-2 it was 0.72 (0.36–1.44) for prostate and 1.95 (1.26–3.00) for colorectal cancer. Results from the BUPA study were consistent with the estimates from the other studies. There were no statistically significant associations with IGFBP-3 and any of the cancer sites considered. Our results suggest that IGF-1, IGF-2, and IGFBP-3 measurements have no value in cancer screening, although IGF-1 and IGF-2 may be of aetiological significance in relation to colorectal and prostate cancer